Background. Fluorine-18 fl uorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer. Because autoimmune pancreatitis is easily misdiagnosed as pancreatic cancer and can be tested for by FDG-PET analysis based on the presence of suspected pancreatic cancer, we attempted to clarify the differences in FDG-PET fi ndings between the two conditions. Methods. We compared FDG-PET fi ndings between 15 patients with autoimmune pancreatitis and 26 patients with pancreatic cancer. The fi ndings were evaluated visually or semiquantitatively using the maximum standardized uptake value and the accumulation pattern of FDG. Results. FDG uptake was found in all 15 patients with autoimmune pancreatitis, whereas it was found in 19 of 26 patients (73.1%) with pancreatic cancer. An accumulation pattern characterized by nodular shapes was signifi cantly more frequent in pancreatic cancer, whereas a longitudinal shape indicated autoimmune pancreatitis. Heterogeneous accumulation was found in almost all cases of autoimmune pancreatitis, whereas homogeneous accumulation was found in pancreatic cancer. Signifi cantly more cases of pancreatic cancer showed solitary localization, whereas multiple localization in the pancreas favored the presence of autoimmune pancreatitis. FDG uptake by the hilar lymph node was signifi cantly more frequent in autoimmune pancreatitis than in pancreatic cancer, and uptake by the lachrymal gland, salivary gland, biliary duct, retroperitoneal space, and prostate were seen only in autoimmune pancreatitis. Conclusions. FDG-PET is a useful tool for differentiating autoimmune pancreatitis from suspected pancreatic cancer, if the accumulation pattern and extrapancreatic involvement are considered. IgG4 measurement and other current image tests can further confi rm the diagnosis.
Introduction
Adenocarcinoma of the pancreas is one of the leading causes of death in Japan and Western countries. The poor prognosis is related to the aggressive biology of this tumor and the diffi culty in early diagnosis. Current image and laboratory tests have improved diagnostic effi ciency to some extent, but insuffi ciently. Recently, fl uorine-18 fl uorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer, and is reported to be a valuable diagnostic modality for differentiating malignant from benign lesions of the pancreas. [1] [2] [3] [4] [5] [6] [7] Therefore, many patients who are suspected of having pancreatic cancer tend to undergo FDG-PET, which is necessary to differentiate between pancreatic cancer and benign pancreatic conditions such as tumor-forming chronic pancreatitis. Among benign pancreatic conditions or tumor-forming chronic pancreatitis that mimic pancreatic cancer, autoimmune pancreatitis now represents a majority of the cases.
Autoimmune pancreatitis, which is a recently proposed disease concept, is characterized by irregular narrowing of the main pancreatic duct and swelling of the pancreatic parenchyma. 8 This disease is associated with various autoimmune phenomena such as hypergammaglobulinemia, histological evidence of lymphoplasmacytic infl ammation, occasional coexistence with other autoimmune diseases, and a favorable response to glucocorticoid treatment. [9] [10] [11] The characteristic clinical features of this disease are a preponderance in elderly men and a high occurrence of obstructive jaundice, which, together with swelling of the pancreatic parenchyma, have sometimes led to the misdiagnosis of pancreatic cancer and unnecessary operations. [11] [12] [13] [14] A previous study disclosed that 2.6% of patients who receive Whipple resection based on the diagnosis of pancreatic cancer show histological fi ndings of autoimmune pancreatitis or lymphoplasmacytic sclerosing pancreatitis. 14 Accordingly, it is urgent to establish a test for differentiating between pancreatic cancer and autoimmune pancreatitis.
We have previously reported that patients with autoimmune pancreatitis have high serum IgG4 concentrations and abundant IgG4-bearing plasma cell infi ltration in the affected organs. 15, 16 IgG4 is to some extent a useful tool for differentiation between autoimmune pancreatitis and pancreatic cancer. 15 To differentiate between the two conditions more accurately, it is recommended that a diagnostic system combining new imaging methods with IgG4 be developed.
Many patients with autoimmune pancreatitis are likely to be among those who receive FDG-PET because of suspected pancreatic cancer. However, FDG-PET cannot always differentiate between the two types of lesions 17, 18 because infl ammatory foci in the pancreas also accumulate FDG. [19] [20] [21] [22] In addition, previous reports have shown that patients with autoimmune pancreatitis also show intense FDG uptake. 19, 23, 24 No reports of systemic studies have convincingly assessed the differences in FDG-PET fi ndings between autoimmune pancreatitis and pancreatic cancer. Because FDG-PET is recommended for many patients who are suspected of having pancreatic cancer, it is urgently necessary to determine the differences in FDG-PET fi ndings between autoimmune pancreatitis and pancreatic cancer. The aim of the present study was to clarify this issue by comparing a suffi cient number of FDG-PET results between autoimmune pancreatitis and pancreatic cancer.
Methods

Study subjects
Between September 1994 and June 2005, we treated and followed 64 patients with autoimmune pancreatitis, 53 men and 11 women aged 38-79 years (median age, 62.4 years). The diagnosis was based on the diagnostic criteria for autoimmune pancreatitis proposed by the Japanese Pancreas Society and the revised proposal. 25, 26 Fifteen of these patients had received FDG-PET between June 2003 and February 2006, 13 men and 2 women, aged 55-75 years (median age, 63.0 years). During the same period, we treated 26 patients with pancreatic cancer who received FDG-PET. The diagnosis of pancreatic cancer was confi rmed by histological fi ndings in 20 patients and on the basis of both typical fi ndings on imaging procedures and the clinical course in six patients.
Laboratory tests
We examined the results of tests of various blood parameters that possibly infl uence the uptake of FDG, including blood sugar 27 and C-reactive protein (CRP), 28 in addition to those of the ordinary blood tests of blood urea nitrogen, creatinine, bilirubin, alkaline phosphatase, amylase, white blood cell count, and CA19-9.
Positron emission tomography
The PET scan was performed with a dedicated PET scanner (Advance Nxi, GE, Milwaukee, WI, USA) in two-dimensional imaging mode. Emission scans were obtained with a 2-3 min acquisition time per table position, requiring 6 or 8 table positions to cover the area from the pelvis fl oor to the head. After emission scanning, transmission scans of the same area were obtained with a 1-2 min acquisition time per table position. The PET image set was reconstructed by the ordered subset expansion maximization algorithm with segmented attenuation correction, and the resulting resolution was approximately 4.3 mm full-width at half-maximum.
After at least 4 h of fasting, the patients were injected with 5 MBq/kg (maximum, 370 MBq) of F-18 FDG intravenously. An early whole-body scan was performed of all patients at 60 min after FDG injection, and a delayed scan of the upper abdomen at 120 min after injection was added in all but three patients.
Data analysis
Focal FDG accumulation was evaluated visually or semiquantitatively by the maximum standardized uptake value (max SUV) in the regions of interest placed over the accumulation in the pancreas on the MIP images at the early and delayed period.
FDG accumulation was assessed in pancreatic and extrapancreatic lesions. In pancreatic lesions, the analysis assessed the following points ( Fig. 1): (1) contour, smooth or irregular; (2) shape, nodular or longitudinal; (3) accumulation pattern, homogeneous or heterogeneous; and (4) extent of accumulation, solitary or multiple. In extrapancreatic lesions, the analysis assessed the levels of accumulation in the salivary gland, hilar lymph node, biliary duct, or retroperitoneal space. Two radiologists (O.K., M.M) assessed the FDG-PET fi ndings independently without knowledge of the results of the other imaging procedures. If disagreement occurred, a fi nal decision was made after discussion.
Statistical analysis for differences was performed by χ-squared analysis or Fisher's exact test, and the MannWhitney test. A level of corrected P < 0.05 was accepted as statistically signifi cant. All reported P values are 2-sided.
All participants provided written informed consent for FDG-PET and invasive tests such as the endoscopic retrograde cholangiopancreatography, and prior to the taking of serum samples. The institutional ethics committee granted permission for the study. Table 1 compares the clinical characteristics of patients between autoimmune pancreatitis and pancreatic cancer. The ratio of men to women was signifi cantly higher among patients with autoimmune pancreatitis than among those with pancreatic cancer. The age distribution was equivalent in both groups. We found no signifi cant differences in the frequency of hyperglycemia or serum levels of fasting blood sugar or CRP. In addition, we found no signifi cant differences in the serum levels of blood urea nitrogen, creatinine, total bilirubin, alkaline phosphatase, or amylase, or in the white blood cell count. The serum levels of CA19-9 in pancreatic cancer were higher than those in autoimmune pancreatitis.
Results
Comparison of clinical characteristics
Comparison of FDG uptake
Pancreatic lesions
The prevalence and manner of FDG accumulation in the pancreatic lesions were signifi cantly different between autoimmune pancreatitis and pancreatic cancer. Accumulations were observed in all patients with autoimmune pancreatitis, but in only 73.1% of patients with pancreatic cancer ( Table 2 ). The max SUV did not differ signifi cantly between autoimmune pancreatitis and pancreatic cancer in either the early or delayed phase. In addition, there was no signifi cant difference in the ratio of delayed to early max SUV between autoimmune pancreatitis and pancreatic cancer. However, an early max SUV of more than 6.6 was found only in patients with pancreatic cancer (Table 2 , Fig. 2) .
With regard to the accumulation pattern, an irregular contour was more frequently seen in autoimmune pancreatitis than in pancreatic cancer, but the difference was not signifi cant (Table 3) . A nodular shape was signifi cantly more frequent in pancreatic cancer. A longi- tudinal shape was frequently found in autoimmune pancreatitis, and also in the diffuse type of pancreatic cancer (Table 3) . Heterogeneous accumulation was found in almost all cases (14/15) of autoimmune pancreatitis, and signifi cantly more frequently than in pancreatic cancer. Homogeneous accumulation was found in pancreatic cancer (Table 3) . Signifi cantly more cases of pancreatic cancer showed solitary localization. Multiple localizations indicated autoimmune pancreatitis (Table 3) . Extrapancreatic lesions FDG uptake in the hilar lymph node was signifi cantly more frequent in patients with autoimmune pancreatitis than in those with pancreatic cancer. FDG uptake by the lachrymal gland, salivary gland, biliary duct, and retroperitoneal space was seen only in autoimmune pancreatitis, though no signifi cant difference was found betw een the two groups (Table 4) .
Representative cases
Representative cases of pancreatic cancer and autoimmune pancreatitis are shown in Fig. 1 . Typical FDG-PET fi ndings for pancreatic cancer are a smooth contour, nodular shape, homogeneous accumulation, and solitary localization ( Fig. 1 A, C) , whereas those for autoimmune pancreatitis are an irregular contour, longitudinal shape, heterogeneous accumulation, and multiple localizations with extrapancreatic lesions (Fig. 1 B, D) .
Discussion
We examined the clinical utility of FDG-PET for differentiation between autoimmune pancreatitis and pancreatic cancer and obtained the following interesting fi ndings. First, FDG-PET uptake was signifi cantly more frequent in autoimmune pancreatitis than in pancreatic cancer. Second, the accumulation pattern in FDG-PET images can potentially be used to discriminate between the two conditions. Third, FDG uptake by extrapancreatic organs may assist in the differentiation between the two conditions. These results suggest that FDG-PET might be used to select autoimmune pancreatitis patients among patients with suspected pancreatic cancer; these patients should then undergo IgG4 measurement or other image tests to confi rm the diagnosis of autoimmune pancreatitis. Though FDG-PET is a sensitive diagnostic modality for detecting malignant tumors, infl ammation can give rise to FDG uptake in the same intensity range as a pancreatic neoplasm. 18 In chronic pancreatitis, tumors detected by FDG-PET consist of degenerative necrosis surrounded by granulation tissue. 29 Autoimmune pancreatitis also causes intense FDG uptake by the pancreas. 23, 24 The present study showed FDG uptake in all 15 patients with autoimmune pancreatitis, whereas 19 of 26 patients (73.1%) with pancreatic cancer showed FDG uptake. In contrast, previous studies have found that the sensitivity of FDG uptake to be higher ) in patients with pancreatic cancer, and lower (83% 24 ) in those with autoimmune pancreatitis. Although the exact reasons for this discrepancy are unknown, FDG-PET can be considered to be a sensitive modality for detecting autoimmune pancreatitis.
Because FDG uptake is infl uenced by various factors other than disease state, we checked the differences in these infl uencing factors between the two conditions. First, patients with high serum glucose levels showed high false-negative results because of decreased FDG uptake by tumors. 26 Second, acute exacerbation of chronic pancreatitis may lead to an incorrect result in static FDG-PET imaging, because acute pancreatitis clearly shows an increased SUV with ranges similar to those for pancreatic cancer. 2 Third, FDG-PET may be falsely positive if CRP is elevated. 28 We found no significant differences in the frequency of hyperglycemia or fasting serum levels of glucose, amylase, CRP, or white blood cell count between autoimmune pancreatitis and pancreatic cancer. Furthermore, no signifi cant differences were found in blood tests for renal functions, biliary enzymes, or total bilirubin. Accordingly, the present FDG-PET results were not infl uenced by these factors and represent the disease state of autoimmune pancreatitis or pancreatic cancer.
The next question is how to differentiate between autoimmune pancreatitis and pancreatic cancer in FDG-PET images. Some reports have described that SUV is higher in malignant tumors than in benign lesions, with a delayed SUV value of >4.0 in pancreatic cancer, of 3.0-4.0 in chronic pancreatitis, and of <3.0 in controls. 2 We found that an early max SUV of more than 6.6 only in cases of pancreatic cancer, which may be helpful in differentiation to some extent. However, the present study showed no signifi cant difference in max SUV between the two conditions. The accumulation pattern of FDG possibly discriminates between the two conditions. A nodular shape was frequently seen in pancreatic cancer, whereas a longitudinal shape was more frequently seen in autoimmune pancreatitis. Heterogeneous accumulation was found in almost all cases of autoimmune pancreatitis, whereas homogeneous accumulation was observed in pancreatic cancer. Most cases of pancreatic cancer showed solitary localization, whereas autoimmune pancreatitis showed multiple localization in the pancreas. Accordingly, typical FDG-PET fi ndings for autoimmune pancreatitis are an irregular contour, longitudinal shape, heterogeneous accumulation, and multiple localization, whereas those for pancreatic cancer are a smooth contour, nodular shape, homogeneous accumulation, and solitary localization. A previous study also showed that characteristic FDG accumulation in autoimmune pancreatitis is diffuse, but if it is focal, differentiation from pancreatic cancer is diffi cult. 24 The longitudinal FDG uptake found in autoimmune pancreatitis is due to diffuse distribution of the infl ammatory process, and FDG uptake by infl ammatory cells possibly results in heterogeneous accumulation because of the scattered distribution of infl ammatory cells. However, diffuse-type pancreatic cancer may also show a similar longitudinal shape, though such cases are rare. The nodular and homogeneous accumulation of FDG found in pancreatic cancer is possibly due to a restricted and condensed distribution of tumor cells and active outer growth. FDG uptake by extrapancreatic organs may assist in differentiation between the two conditions. The prominent features of autoimmune pancreatitis involve a variety of extrapancreatic complications: sclerosing cholangitis, lachrymal and salivary gland swellings, hypothyroidism, hilar lymphadenopathy, retroperitoneal fi brosis, interstitial pneumonia, and tubulointerstitial nephritis. 32 Some of these extrapancreatic lesions show pathological fi ndings similar to those of pancreatic lesions, including infi ltration of abundant IgG4-bearing plasma cells. 7, 9 The present study showed that FDG uptake by the hilar lymph node is a useful fi nding for the diagnosis of autoimmune pancreatitis, though extrapancreatic accumulation of FDG in the lymph nodes is diffi cult to differentiate from metastasis of a malignancy to lymph nodes. In addition, FDG uptake by the lachrymal gland, salivary gland, biliary duct, and retroperitoneal space were found only in autoimmune pancreatitis. Concomitant FDG uptake by these organs supports the diagnosis of autoimmune pancreatitis.
Severe lymphocytic infi ltration in the pancreatic tissue suggests the possibility that gallium-67 citrate (Ga-67) accumulates in the pancreas, because Ga-67 concentrates in lymphoid cells. Previously, we performed Ga-67 scintigraphy in 24 patients with autoimmune pancreatitis before and after 4 weeks of corticosteroid therapy, and found marked Ga-67 accumulation in 16 patients (67%) in the pancreas, in 16 patients (67%) in the hilar lymph node, and in fi ve patients (21%) in the salivary gland before corticosteroid therapy. These positive images changed to negative after 4 weeks of therapy. 33 Because we have no data concerning Ga-67 scintigraphy for pancreatic cancer, we did not evaluate its specifi city in detecting autoimmune pancreatitis. However, FDG-PET seems to have superior sensitivity for detection of autoimmune pancreatitis than Ga-67 scintigraphy. In detecting extrapancreatic lesions, such as hilar lymphadenopathy and salivary gland lesions, FDG-PET images were comparable to those of Ga-67 scintigraphy. Though Ga-67 scintigraphy markedly showed negative images after steroid therapy, we could not confi rm the utility of FDG-PET in follow-up because we had no FDG-PET images after corticosteroid therapy.
The mechanism of accumulation of FDG in autoimmune pancreatitis is thought to be massive infi ltration of activated lymphocytes. Consistent with this, a similar FDG-PET pattern has been reported in malignant lymphoma of the pancreas with extrapancreatic accumulation. 34 Similar to lymphoma, autoimmune pancreatitis also shows a high serum concentration of soluble interleukin 2 receptor and β2-microglobulin. 33 Accordingly, a possible diagnosis of lymphoma should be considered for cases with a similar FDG-PET pattern to autoimmune pancreatitis.
In conclusion, FDG uptake was found in all patients with autoimmune pancreatitis, suggesting that FDG-PET may be a useful tool for selecting patients with possible autoimmune pancreatitis among patients with suspected pancreatic cancer, by taking into account the accumulation pattern and extrapancreatic involvement. IgG4 measurement and current image tests can confi rm the diagnosis of autoimmune pancreatitis in these selected patients.
